Literature DB >> 12544687

Living donor liver transplantation in adults.

Christoph E Broelsch1, Andrea Frilling, Giuliano Testa, Massimo Malago.   

Abstract

Adult-to-adult living donor liver transplantation (LDLT) using right hemi-liver has become a promising treatment modality for patients with end-stage liver disease. The rapid adoption of the procedure has been triggered mainly by the significant gap between available cadaver grafts and the number of patients on the waiting list for liver transplant. Since the arguments against LDLT focus only on the safety of the donor, the demonstration that the donor operation can be performed with minimal morbidity will make it more ethically acceptable. The advantages of LDLT are the possibility of performing an elective operation, access to a graft in best condition, and the possibility of lowering the likelihood of death while waiting for a suitable organ. As well as the standard indications for liver transplantation, LDLT opens up the possibility of treatment of patients with borderline indications. Further improvement of surgical and medical technology, careful long-term follow-up of donors and recipients, and profound analysis of socioeconomic aspects are essential issues for the transplantation community. Copyright 2003 Lippincott Williams & Wilkins

Entities:  

Mesh:

Year:  2003        PMID: 12544687     DOI: 10.1097/00042737-200301000-00002

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  9 in total

1.  Computer-assisted operative planning in adult living donor liver transplantation: a new way to resolve the dilemma of the middle hepatic vein.

Authors:  A Radtke; S Nadalin; G C Sotiropoulos; E P Molmenti; T Schroeder; C Valentin-Gamazo; H Lang; M Bockhorn; H O Peitgen; C E Broelsch; M Malagó
Journal:  World J Surg       Date:  2007-01       Impact factor: 3.352

2.  Retrospective analysis of the causes of rejection of potential donors for living related liver transplantation.

Authors:  Khalid Abdullah; Hesham Abdeldayem; Ibrahim Abdel-Kader Salama; Khaled Badah; Badriyah Al-Somali; Abdulmajeed Abdulkareem
Journal:  Hepatol Int       Date:  2007-08-23       Impact factor: 6.047

3.  Analysis of postsurgical complications in 75 living liver transplantation donors.

Authors:  Hakan Sozen; Hamdi Karakayali; Gokhan Moray; Aydin Dalgic; Remzi Emiroglu; Mehmet Haberal
Journal:  J Gastrointest Surg       Date:  2006-05       Impact factor: 3.452

Review 4.  Spectrum of biliary complications following live donor liver transplantation.

Authors:  Priya Simoes; Varun Kesar; Jawad Ahmad
Journal:  World J Hepatol       Date:  2015-07-18

5.  Living donor liver transplantation using dual grafts: ultrasonographic evaluation.

Authors:  Qiang Lu; Hong Wu; Lv-Nan Yan; Zhe-Yu Chen; Yu-Ting Fan; Yan Luo
Journal:  World J Gastroenterol       Date:  2010-08-21       Impact factor: 5.742

6.  Evolution of donor morbidity in living related liver transplantation: a single-center analysis of 165 cases.

Authors:  Dieter C Broering; Christian Wilms; Pamela Bok; Lutz Fischer; Lars Mueller; Christian Hillert; Christian Lenk; Jong-Sun Kim; Martina Sterneck; Karl-Heinz Schulz; Gerrit Krupski; Axel Nierhaus; Detlef Ameis; Martin Burdelski; Xavier Rogiers
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

Review 7.  [Acute liver failure. Current aspects of diagnosis and therapy].

Authors:  M Bauer; M Paxian; A Kortgen
Journal:  Anaesthesist       Date:  2004-06       Impact factor: 1.041

Review 8.  Living donor liver transplantation in Europe.

Authors:  Silvio Nadalin; Ivan Capobianco; Fabrizio Panaro; Fabrizio Di Francesco; Roberto Troisi; Mauricio Sainz-Barriga; Paolo Muiesan; Alfred Königsrainer; Giuliano Testa
Journal:  Hepatobiliary Surg Nutr       Date:  2016-04       Impact factor: 7.293

9.  One hundred in situ split-liver transplantations: a single-center experience.

Authors:  Hasan Yersiz; John F Renz; Douglas G Farmer; Garrett M Hisatake; Suzanne V McDiarmid; Ronald W Busuttil
Journal:  Ann Surg       Date:  2003-10       Impact factor: 12.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.